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SUMMARY 
 
Although known since the 1960s that trypsin and chymotrypsin can mimic hormone action in tissues, it 
took until the 1990s to discover that serine proteinases can regulate cells by cleaving and activating a 
unique 4-member family of G-protein-coupled receptors termed ‘proteinase-activated-receptors’ or 
‘PARs’. PAR activation involves the proteolytic exposure of an N-terminal receptor sequence, that folds 
back to function as a ‘tethered’ receptor-activating ligand (TL)’. A key N-terminal arginine in each of 
PARs 1 to 4 has been singled out as a target for cleavage by either thrombin (PARs 1, 3 and 4) or trypsin 
(PARs 2 and 4) to unmask the TL that activates signalling via Gq, Gi or G12/13. Similarly, synthetic 
receptor-activating peptides, corresponding to the exposed ‘TL sequences’ (e.g. SFLLRN---, for PAR1 
or SLIGRL--- for PAR2) can, like proteinase activation, also drive signalling via Gq, Gi and G12/13, 
without requiring receptor cleavage. Recent data show, however, that distinct proteinase-revealed ‘non-
canonical’ PAR tethered-ligand sequences and PAR-activating agonist and ‘antagonist’ peptide 
analogues can cause ‘biased’ PAR signalling e.g. via G12/13-MAPKinase versus Gq-calcium. This 
overview summarizes implications of this ‘biased’ signalling by PAR agonists and antagonists for the 
recognized roles the PARs play in inflammatory settings. 
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INTRODUCTION 
 
Proteinase-mediated signalling. One index of the importance of proteinases for regulating biological 
processes is that more than 2% of the human genome has been found to code for either proteinases 
(colloquially termed: proteases) or their inhibitors (Puente et al., 2005). Thus, in addition to their 
‘classical roles’ as digestive protein-degrading enzymes, it comes as no surprise that proteinases are now 
recognized for their multiple roles in regulating tissue function by both receptor and non-receptor 
mechanisms (Figure 1). For instance, the discovery of hypotensive urinary peptides that also have 
contractile activity in uterine smooth muscle (Werle & Erdos, 1954) heralded the work of Chretien, 
Steiner and their colleagues showing that key hormones like ACTH and insulin are generated by the 
proteolytic processing of larger hormone precursors (Chretien, 2012; Steiner et al., 1967; Steiner, 2011). 
The turnover of peptide agonists by proteolysis to reduce cell signalling, e.g. by neutral endopeptidase 
cleavage of neurokinins, is of equal importance. Thus, proteinases can regulate cellular signalling events 
by cleaving a variety of targets, including pro-hormones, kininogens, chemokine and cytokine 
precursors and even growth factor receptors like the one for insulin, to name a few. For instance, the 
‘insulin-like’ actions of trypsin and other proteinases (Rieser and Rieser, 1964; Rieser,1967; Kono & 
Barham, 1971) can be seen to result from the cleavage of the extracellular alpha-subunit of the insulin 
receptor, so as to abolish inhibitory control of receptor function (Shoelson et al, 1988). At higher 
concentrations, trypsin was found to ‘disarm’ the insulin receptor thereby preventing its ability to bind 
insulin and signal (Cuatrecasas 1969; Cuatrecasas, 1971). By the 1970s it was also clear that like insulin 
and epidermal growth factor, thrombin and trypsin could stimulate cell culture mitogenesis by a 
receptor-like mechanism (Burger, 1970; Sefton & Rubin, 1970; Chen & Buchanan, 1975; Carney & 
Cunningham, 1977; Carney & Cunningham, 1978); but the mechanisms for these actions of the 
proteinases were not known at the time. As outlined in the following section, it was the search for the 
‘thrombin’ receptor, responsible for stimulating human platelet aggregation and mitogenesis in cultured 
hamster cells that ultimately led to the discovery of the G-protein-coupled proteolytically-activated 
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receptor (PAR) responsible for these actions of thrombin (Rasmussen et al., 1991; Vu et al., 1991). Thus, 
there are multiple mechanisms whereby proteinases can signal to cells, as outlined in Figure 1, in 
addition to regulating PAR activity, which will be the main focus of this overview. The PAR- and non-
PAR mechanisms of proteinase signalling (Figure 1) can be seen as complementary ways in which 
tissue-derived proteinases can play a role in physiologically important processes involving inflammation.  
Signalling by thrombin and discovery of the four PAR GPCR family members. As mentioned above, 
two laboratories independently cloned a G-protein-coupled receptor responsible for the ability of 
thrombin to regulate human platelet function and to stimulate cell replication in cultured hamster cells. 
A key feature of the cloned receptor observed in both laboratories was its ability, presumably by 
stimulating Gq, to mobilize intracellular calcium when activated by thrombin in an oocyte expression 
system (Rasmussen et al., 1991; Vu et al., 1991). It was also known at the time that thrombin signalling 
could inhibit adenylyl cyclase, presumably by triggering Gi (Vouret-Craviari et al., 1992). Thus, at the 
outset, it was realized that thrombin, via its cloned receptor (now termed PAR1, with its gene designated, 
F2R) could couple to multiple G-proteins in order to generate cell signals. The unusual mechanism that 
activates this unique G-protein-coupled receptor (Vu et al., 1991) involves the proteolytic unmasking of 
a cryptic N-terminal receptor sequence that while remaining attached folds back to act as a ‘tethered 
ligand’ (TL), which triggers signalling (Figure 2, left panel). Surprisingly, synthetic peptides with 
sequences corresponding to the newly exposed TL sequence can stimulate receptor signalling without 
the need for proteolytic activation, albeit at 100-1000-fold higher concentrations than those of the 
proteinase agonists (Figure 2, right-hand panel). Thus, on its own, the sequence, SFLLRNPNDKYEPF, 
was found to mimic the action of thrombin on human platelets (Vu et al., 1991). However it rapidly 
became apparent from structure-activity studies of the actions of this peptide and its analogues that there 
was a distinct ‘thrombin receptor’ on rodent platelets that could not be activated by such peptides 
(Kinlough Rathbone et al., 1993) and that a receptor different from the ‘thrombin receptor’ cloned by Vu 
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and colleagues in 1991 was present in vascular and gastric tissue preparations (Hollenberg et al., 1993; 
Al-Ani et al., 1995). The fortuitous cloning of murine PAR2, found when searching a genomic library 
for a substance K receptor (Nystedt et al., 1994) and the subsequent cloning of human PAR2/F2RL1 
(Bohm et al., 1996) paved the way for the subsequent cloning of the other two members of the PAR 
family, namely PAR3/F2RL2 (Ishihara et al., 1997) and PAR4/F2RL2 (Kahn et al., 1998; Xu et al., 
1998). All of the PARs have in their N-terminal sequences a principal serine proteinase-targeted 
arginine at which cleavage exposes a distinct ‘tethered ligand’ for each receptor, as summarized in Table 
1. Unmasking of such tethered ligands in PARs 1 and 4 by thrombin and in PAR2 by trypsin stimulates 
cell signalling that involves a number of G-proteins (Gq, Gi, G12/13). Further, the synthetic peptides 
based on the revealed TL sequences can also stimulate comparable signalling via the ‘partner’ G-
proteins. As outlined in Table 1, it has been possible to synthesize PAR-selective activating peptides to 
evaluate the impact of signalling by PARs 1, 2 and 4 in a variety of cultured cell and in-vivo contexts. 
PAR3 appears to function as a ‘co-factor’ for activation of PAR1 (Nakanishi-Matsui et al., 2000) and 
peptides derived from its tethered ligand sequence are able to activate both PARs 1 and 2 (Hansen et al., 
2004). In certain circumstances, PAR3 is reported to signal on its own (Ostrowska & Reiser, 2008), but 
its general role in regulating tissue function remains to be fully elucidated.  
To sum up, the ability of serine proteinases to regulate tissue function can now be seen to include 
activation of PARs in addition to the other mechanisms illustrated in Figure 1. The unusual features of 
the PARs are now well-appreciated (Figure 2) in terms of:  (1) their unique mechanism of activation, 
involving the exposure of a tethered ligand (left Panel, Figure 2), (2) their ability to be activated 
selectively by receptor-specific synthetic activating peptides, based on the sequences of the revealed 
tethered ligand (Right Panel, Figure 2; Table 1) and (3) their ability to be activated or 
inactivated/disarmed selectively by a variety of serine proteinases. For instance, thrombin activates 
PARs 1 and 4, but not PAR2; trypsin at low concentrations can activate PAR2 and PAR4, but dis-arms 
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PAR1 (Kawabata et al., 1999); and Pseudomonas elastase dis-arms trypsin-mediated activation of PAR2 
(Dulon et al., 2005). It is important to recognise that a proteinase which cleaves C-terminal to the 
tethered ligand domain sequence shown in the left panel of Figure 2 (…SKGRSLIGRL…) will 
‘disarm’’ the PAR to prevent its activation by an enzyme (e.g. trypsin) that acts via the ‘tethered ligand’.  
Thus, enzymatically, the PARs can be seen to have their circulating proteinase ‘agonists’ that unmask 
the tethered ligand as well as circulating proteinases that act indirectly as ‘antagonists’ by cleaving 
downstream of the TL and removing it from the receptor. The unanswered questions still are, however: 
(1) Which are the endogenous proteinases that can regulate PAR function in vivo and (2) Do the actions 
of the synthetic tethered ligand PAR-activating peptides stimulate the same signals as the proteinase-
revealed tethered ligands? As will be seen in the following sections, research aimed at answering these 
questions has revealed the ability of the PARs to signal in a biased way. 
BIASED PAR SIGNALLING AND THE MOBILE OR FLOATING RECEPTOR MODEL 
Receptor plasticity and biased PAR signalling. Early on, from structure-activity studies with the PAR-
activating peptides (PAR-APs), it was appreciated that signalling by the enzyme (e.g. thrombin for 
PAR1) was not completely reproduced by the receptor-activating peptides. For instance the mitogenic-
MAPKinase stimulating action of thrombin in hamster fibroblasts was not matched by the action of the 
receptor peptide agonist (Vouret-Craviari et al., 1992). Further, studies of PAR1 with mutations in its 
extracellular domains showed that the docking-activation mechanisms for the PAR1-activating peptides 
(most mutations affected PAR-AP-induced responses) differed substantially from activation by the 
thrombin-revealed tethered ligand (responses largely unaffected) (Blackhart et al., 2000). Our own work 
with PAR2 then showed that mutations in the extracellular loop-2 domain (wild-type ‘EE’ to mutated 
‘RR’) markedly affected calcium signalling by the PAR2-activating peptide, SLIGRL-amide (Figure 
3A: large shift to the right to lower potency), but had little or no effect on calcium signalling by the 
trypsin-revealed tethered ligand (Figure 3B: no shift to the right for the mutant ‘RR’ vs wild-type ‘EE’ 
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receptor) (Al-Ani et al., 2002). Subsequently, we found that by inserting alanine mutations into the N-
terminal ‘tethered’ ligand sequence of rat PAR2 (SLIGRL---), even the trypsin-revealed sequence, 
SLAAAA---, was sufficient to trigger calcium signalling when the receptor was activated by trypsin 
(Figure 4, red arrow/red font); but the revealed sequence, AAIGRL--- failed to do so with any efficiency 
(Figure 4, bottom, blue arrow/blue font). Of note, the trypsin-revealed tethered ligand with a mutated 
sequence, LSIGRL---failed to cause calcium signalling (Figure 4, blue font and arrow, X-axis). Quite 
surprisingly, the synthetic peptide based on the mutated-unmasked tethered ligand (SLAAAA-amide) 
failed to activate PAR2 calcium signalling, but was found to activate PAR2 MAPKinase signalling 
(Table 2 in Al-Ani et al., 2004, and Figure 5: Ramachandran et al., 2009). Thus, we concluded that for 
both PARs 1 and 2, the change in receptor conformation caused by the exposed tethered ligand differed 
from changes triggered by the synthetic PAR-activating peptides. Further, we had identified a PAR2 
biased agonist (SLAAAA-amide) that could trigger MAPKinase activation but not calcium signalling. 
Previous work with a PAR1 agonist, YFLLRNP, pointed to its ability to be a ‘biased’partial agonist for 
PAR1, able to trigger human platelet shape change but not aggregation (Rasmussen et al., 1993). 
Moreover, it was evident that like other GPCRs, the PARs were capable of ‘functional selectivity’ or 
‘biased’ signalling (Kenakin, 2011; Kenakin & Miller, 2010). What was not determined was whether 
endogenous proteinase activation of the PARs might also activate the receptors in a ‘biased way’ like the 
synthetic peptide agonists. Further, the mechanism that could account for biased PAR signalling had not 
been determined. 
PAR dynamics and biased signalling. As illustrated in Figure 6, the ability of an individual receptor to 
activate multiple signalling pathways, as described by the‘mobile’ or ‘floating’ receptor model put 
forward some time ago (Jacobs & Cuatrecasas, 1976; de Haën, 1976), depends on its diffusion in the 
plane of the membrane to interact with multiple ‘effectors’ (e.g. different G-proteins); and in the case of 
GPCRs like PAR2, to interact with beta-arrestin, forming an internalized G-protein-independent 
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signalling scaffold (DeFea, 2008).  Using PAR2 as a prototype for the PARs, we employed a C-
terminally-YFP-tagged receptor (1) to follow the dynamics of PAR2 upon activation by either trypsin or 
a PAR2-activating peptide (Figure 7A) and (2) to monitor its interaction with rLuc-tagged beta-arrestin, 
to generate a bioluminescence resonance energy transfer signal (BRET: Figure 7B, red arrow, cartoon at 
bottom). Upon activation of PAR2 by either trypsin or the PAR-activating peptide, SLIGRL-NH2, the 
receptor interalizes (Figure 7A, panels ii and iii and histograms) in parallel with its interaction with beta-
arrestin that generates an increase in BRET emission (Figure 7B, panels A and B, red arrows). This 
activation of the wild-type receptor by either trypsin or SLIGRL-NH2 is accompanied by an increase in 
intracellular calcium and an activation of MAPKinase.  In contrast, a mutated PAR2 tethered ligand with 
the trypsin-revealed sequence, /LSIGRL---, which does not signal via calcium (Figure 4, bottom X-
axis), can indeed activate MAPKinase (Figure 8A); but activation of the mutant  /LSIGRL--- receptor 
by trypsin did not result either in receptor internalization (Figure 8B, lower panels and histograms) or in 
an interaction with beta-arrestin (not shown: Ramachandran et al., 2009). Thus, the dynamics of PAR2 
upon activation of the wild-type and mutant receptors we studied (internalization or not) can be 
correlated with ‘biased’ receptor signalling (internalization = Calcium plus MAPKinase; non-
internalization = MAPKinase only). The mechanisms of signalling by the receptor upon remaining at the 
plasma membrane instead of being internalized remain to be explored. The next step was to determine if 
endogenous PAR2 activating enzymes could trigger biased signalling, in step with a restricted receptor 
interaction with beta-arrestin and a lack of internalization. 
Biased PAR activation by endogenous proteinases and distinct receptor dynamics: the discovery of 
non-canonical proteinase-revealed ‘tethered ligands’and signalling by non-canonical PAR1 tethered 
ligands. The first clear evidence that PARs can signal by an enzyme-unmasked ‘non-canonical’ tethered 
ligand generated by cleavage at sites other than the target arginine (e.g. R41 /S42 in human PAR1) came 
from studies of the chemotactic properties of matrix-metalloproteinase-1 (MMP-1) (Boire et al., 2005). 
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By cleavage of human PAR1 at the D39/P40 site, which is located 2-amino acid residues to the N-
terminal side of the thrombin cleavage site at R41-S42, thus revealing a TL sequence, PRSFLLR---,  
MMP-1 triggers PAR1 signalling (Boire et al., 2005; Trivedi et al., 2009) . This ‘non-canonical’ PAR1 
tethered ligand causes the receptor to signal in many ways like the ‘classical TL’ unmasked by thrombin 
(TL = SFLLRN---); and the receptor-derived ‘non-canonical’ ‘TL’ peptide (PRSFLLRN) was a full 
agonist for PAR1-dependent Rho and p38 MAPK signalling in platelets (Triverdi et al., 2009). In our 
own hands, the peptide also triggers PAR1-mediated calcium signalling, but at much higher 
concentrations than for activating p42/44 MAPKinase. Thus, the peptide appears selective for 
MAPKinase and Rho signalling relative to calcium, but the‘biased’ nature of MMP1-generated ‘non-
canonical’ PAR1 tethered ligand remains to be fully characterized.  
A ‘biased’ signalling pathway for PAR1 has also been observed for its stimulation by Activated Protein-
C, (APC) compared with PAR1 activation by thrombin (Mosnier et al., 2012; Schuepbach et al., 2012; 
Russo et al., 2009). Thus, thrombin activation of PAR1 triggers RhoA, but not Rac1 signalling, along 
with an increase in endothelial barrier permeability. Conversely, APC activation of PAR1 causes the 
opposite: stimulation of Rac1 but not RhoA that results in a decrease in endothelial barrier permeabilty 
(Russo et al., 2009). This biased signalling by APC is dependent not only on a specific location of PAR1 
in a caveolar environment (Russo et al., 2009), but also on the generation of a novel ‘non-canonical’ 
tethered ligand by APC cleavage at the R46//N47, position of human PAR1, to expose a tethered ligand 
with the sequence: N47PNDKYEPF— (Mosnier et al., 2012; Schuepbach et al., 2012). It is of 
considerable interest that the ‘APC-generated’ TL sequence no longer contains the arginine at position 
46, which was proposed in the past to interact with the glutamic acid at position 260 of the extracellular 
loop 2 of PAR1 (Nanevicz et al., 1995). Thus, one can conclude that the APC-generated non-canonical 
tethered ligand and its sequence-derived biased PAR1-activating peptide dock with the receptor 
differently than the thrombin-generated ‘canonical’ TL sequence, SFLLRN---. Indeed, APC-activated 
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PAR1 in endothelial cells is retained on the cell surface, even when cells are subsequently exposed to 
thrombin (Schuepbach et al., 2008). Our new work indicates that proteinases other than MMP1 and APC 
can also generate distinct ‘biased’ ‘non-canonical’ tethered ligands to regulate PAR1 function (Mihara et 
al., 2013) 
Biased PAR1 signalling by cockroach allergen proteinase E1. In common with many insect allergens, 
cockroach allergen has been found to contain serine proteinase activity that can activate PAR2 
(Arizmendi et al., 2011). Since PAR2 evidently plays a role in the allergen sensitization process 
(Arizmendi et al., 2011), we wondered if the three serine proteinases present in cockroach allergen, as 
detected by a biotinylated serine proteinase Activity-Based Probe (ABP: Figure 9A,), might also activate 
PAR1. As shown by the activity-based probe biotin blots in Figure 9, we have separated the three 
cockroach enzymes chromatographically, as indicated by the presence of only one ABP-labeled enzyme 
in each isolated fraction (E1, E2 and E3: Figure 9A, upper left). In a human PAR1-expressing KNRK 
cell line, thrombin was able to activate both calcium signalling and MAPKinase (Figure 9 B, left; Figure 
9C, left). However cockroach enzyme E1, at a concentration that activated PAR1 MAPKinase (4 U/ml: 
Figure 9B, right) was not able to activate calcium signalling (Figure 9C, right). Thus, like Activated 
protein C, the cockroach allergen serine proteinase E1 is able to cause biased signalling via PAR1. The 
presumed ‘non-canonical’ tethered ligand responsible for PAR1 biased signalling triggered by the 
cockroach enzyme E1 remains to be determined. 
Signalling by a non-canonical PAR2 tethered ligand. Our interest in the potential roles of neutrophil or 
pathogen-derived proteinases in inflammatory settings like cystic fibrosis led us to the observation that 
Pseudomonas aeruginosa elastase can ‘disarm’ PAR2, thereby preventing its activation by trypsin 
(Dulon et al, 2005). We next evaluated the impact of human neutrophil elastase on PAR2 function. As 
expected, this enzyme ‘dis-armed’ PAR2, so that trypsin is no longer able to activate it (Figure 10A, 
left-hand tracing). To our surprise, however, we found that neutrophil elastase could activate PAR2 
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MAPKinase signalling (Figure 10A, right hand panel) without triggering calcium signalling (left-hand 
tracing, Figure 10A). This result echoed the data we had obtained previously for trypsin-mediated 
activation of the mutant PAR2 with a tethered ligand sequence (‘//LSIGRL---‘) that does not activate 
calcium signalling (Figure 4, X-axis) but triggers MAPKinase (Figure 8A). Further, PAR2 activation by 
human neutrophil elastase does not stimulate its interaction with beta-arrestin, unlike activation by either 
trypsin or a PAR-activating peptide (Figure 10B). In keeping with the distinct receptor dynamics we 
observed for the PAR2 ‘//LSIGRL---‘ tethered ligand mutant’ (no internalization: Figure 8B), elastase-
activation of the receptor does not cause PAR2 internalization, whereas trypsin does (Figure 11). Thus, 
the biased PAR2 signalling triggered by the neutrophil elastase ‘non-canonical’ tethered ligand, which 
involves a selective activation of MAPKinase via G12/13, is both spatially and kinetically distinct from 
signalling activated by the ‘canonical’ tethered ligand revealed by trypsin (Ramachandran et al., 2011) 
and is independent of an interaction with beta-arrestin.  Using synthetic peptides representing the N-
terminal extracellular sequence of rat PAR2, we were able to predict the likely site at which neutrophil 
elastase generates its ‘non-canonical’ tethered ligand (underlined: DEFSAS// VLTGKLTTVFL---) 
(Ramachandran et al., 2011). However, a synthetic peptide based on this sequence (VLTGKLTTVFL-
NH2) did not activate PAR2 either for calcium or MAPKinase signalling. Thus, both PAR2 and PAR1 
can caused biased signalling when activated by endogenous proteinases; and this biased signalling 
generated by the unmasking of ‘non-canonical’ tethered ligands in PARs 1 and 2 is caused by 
mechanisms that are distinct from signalling triggered by the ‘canonical’ tethered ligands in terms of 
receptor dynamics. Whether proteinase activation can cause biased signalling by PAR4 remains to be 
determined, but appears highly likely. 
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BIASED PAR ANTAGONISTS AND THEIR THERAPEUTIC POTENTIAL FOR 
INFLAMMATORY DISEASES 
Biased PAR antagonists. As outlined in more detail elsewhere (Ramachandran et al., 2012), the 
development of small molecule antagonists for PAR1 has been successful (e.g. Maryanoff et al, 2003; 
Chackalamannil et al,. 2008), whilst the emergence of useful PAR2 antagonists has lagged behind. For 
the PAR1 antagonists, screening that resulted in the identification of ‘lead’ compounds involved 
measurements of either human platelet aggregation or calcium signalling. Thus, despite the effectiveness 
of the PAR1 antagonists to block thrombin-induced platelet aggregation, the ability of those compounds 
to affect the receptor in a biased way has never been evaluated in detail. Similarly, the PAR2 antagonists 
developed successfully to date have been evaluated primarily for their block of agonist-induced calcium 
signalling (Suen et al., 2012; Sevigny et al., 2011), but not for their ‘biased’ antagonist or agonist 
properties. Given the prime focus of our laboratory on PAR2-induced inflammation, we studied the 
properties of GB88 and P2-pal-18S pepducin in terms of their potential biased antagonist activities. 
As shown in Figure 12A, GB88 does indeed block agonist-stimulated PAR2 calcium signalling in 
keeping with previous observations (Suen et al., 2012; Lohman et al., 2012a); but on its own, GB88 
activates MAPKinase at levels equivalent to those achieved by either trypsin or the PAR2 peptide 
agonist, 2-furoyl-LIGRLO-NH2 (Figure 12B) (Han, 2008; Suen et al., 2013). In accord with its ability to 
activate MAPKinase via PAR2, GB88 promotes the interaction of the receptor with beta-arrestin (Figure 
13A). However, GB88 does not itself trigger receptor internalization (Figure 13B, left panel); nor does it 
prevent internalization of PAR2 activated by either trypsin or 2-furoyl-LIGRLO-NH2 (Figure 13B, 
right-hand panels). Thus, GB88 behaves as a ‘biased’ PAR2 agonist-antagonist, blocking calcium 
signalling stimulated by either trypsin or a PAR2-activating peptide, but simultaneously activating 
MAPKinase and other signalling pathways (Suen et al., 2013). Further work evaluating the full extent of 
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signalling modulated by GB88 and its ability to promote the interaction of PAR2 with beta-arrestin 
merits attention. 
Like GB88, the pepducin PAR2 antagonist, P2pal-18S pepducin, does not trigger calcium signalling on 
its own and is able to block PAR2-mediated calcium signalling (Sevigny et al., 2011; Figure 14A). 
However, this antagonist does not prevent the interaction of agonist-triggered PAR2 with beta-arrestin 
(Figure 14B). Thus, one can predict that like GB88, P2pal-18S pepducin will block only a subset of 
PAR2 responses, thus functioning as a ‘biased’ antagonist. This issue clearly merits further study. 
Anti-inflammatory actions of ‘biased’ PAR2 antagonists. Despite the ‘biased’ block of PAR2 action 
caused by either GB88 or the P2pal-18S pepducin outlined in the previous paragraph, both PAR2 
antagonists have been encouragingly successful in attenuating inflammation in vivo in a number of 
model systems (Lohman et al., 2012a and 2012b; Sevigny et al., 2011; Suen et al,. 2012). In particular, 
both antagonists can block PAR2- induced paw oedema (Figure 15, GB88, left panel) and neutrophil 
infiltration (Figure 15, P2pal-18S, right panel) in a murine peripheral inflammation model (Sevigny et 
al., 2011; Lohman et al., 2012a; Suen et al,. 2012), that we have shown in the past to involve a 
neurogenic component (Vergnolle et al., 1999; Steinhoff et al., 2000). Thus, it is likely that in the paw 
oedema setting, the antagonists are affecting PAR2 calcium signalling both on the neuronal elements as 
well as on the endothelial and inflammatory cells. However, our data indicate that these antagonists 
would NOT block the beta-arrestin signalling mechanisms responsible for the migration of eosinophils 
into the site(s) of airway inflammation in an in vivo asthma model (Nichols et al., 2012). Thus, the 
biased nature of the pepducin and GB88 antagonists predict that they will block only a subset of the 
inflammatory responses due to PAR2 activation. This situation may be an advantage, in that a role for 
PAR2 in the resolution of inflammation is likely; and the selective block of the calcium signalling arm 
of PAR2, whilst retaining the beta-arrestin and other pathways triggered by PAR2 internalization, may 
fortuitously accelerate the ‘healing process’ in which PAR2 may participate. Thus, the therapeutic 
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potential of biased PAR antagonists should not be overlooked. Indeed, the differential nature of the 
pathways being affected by each biased ligand (either agonist or antagonist) will dictate which disease 
context will benefit from their therapeutic use. 
SUMMING UP 
Given the ‘hormone-like’ role of proteinases, their inflammatory and pathophysiological impact will be 
mediated by a number of mechanisms quite apart from the regulation of PAR activity (Figure 1). 
Nonetheless, PARs will undoubtedly be found to play important roles in a variety of settings including 
cardiovascular, inflammatory, and neurodegenerative diseases as well as cancer. The unusual 
mechanism of PAR regulation by proteolysis makes these receptor systems unique in having not only a 
number of molecularly distinct circulating full and biased agonists (e.g. trypsin vs. elastase for PAR2), 
but also multiple circulating proteinase ‘antagonists’ that can silence the receptors by dis-arming. The 
importance of the PARs can be seen in certain inflammatory settings like arthritis, colitis, tumour 
invasion and central nervous system neurodegeneration, where mouse knockout studies suggest that the 
PARs can play key roles and may therefore be attractive therapeutic targets (see Ramachandran et al., 
2008; Adams et al., 2011; Ramachandran et al., 2012). Thus, the development of therapeutically useful 
antagonists for PARs 1 and 2 merit continued efforts, despite the somewhat limited success to date for 
the clinical use of PAR1 antagonists in the setting of vascular disease (see Ramachandran et al., 2012 for 
discussion). To continue this search for PAR-targeted drugs, we suggest considering seriously, the 
potential utility of biased antagonists that may be able to diminish acute inflammatory responses, but 
also retain a PAR-mediated impact on the resolution of inflammation following the initial inflammatory 
insult. Further, biased PAR agonists may be of value in certain settings, where the localized activation of 
PARs may be advantageous e.g. in the bronchi, where PAR2 activation can cause bronchodilation (e.g. 
Chow et al., 2000). Overall, it is hoped that this overview highlighting the ‘biased’ properties of both 
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endogenous and synthetic PAR agonist and antagonists will stimulate further therapeutic developments 
in this field. 
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FIGURE LEGENDS 
Figure 1. Proteinase-mediated signalling. The cartoon shows 5 distinct ways by which proteinases can 
cause cell signals, ranging from the generation or degradation of active peptides (top) to the activation of 
proteinase-activated receptors (PARs: bottom) 
 
Figure 2. Activation of PAR2 by proteinase (left) or PAR-activating peptide (right). The cartoon shows 
the activation of PARs either by the unmasking of a receptor-tethered activating ligand (left: SLIGRL--- 
for PAR2) or by a synthetic peptide with a sequence in common with the revealed ‘tethered ligand’ 
(right: SLIGRL-NH2). 
 
Figure 3. Differences in signalling by PAR2-AP vs Tethered Ligand in a mutant PAR2 ‘SR/RR’ 
receptor. The scheme at the top shows a mutant PAR2 with a ‘PRR’ (Upper right mutant sequence, RR, 
TOP), versus the wild-type ‘PEE’ sequence (Upper-right, wild-type sequence, EE) in extracellular loop-
2, but with a wild-type sequence for the unmasked ‘tethered ligand’ (R/SLIGRLDT: SR, left tethered 
ligand sequences identical in mutant and wild-type receptors). The ‘RR’ mutant receptor shows a 
reduced sensitivity to the synthetic PAR2-activating peptide, SLIGRL-NH2 (compare SR/EE receptor 
with the SR/RR receptor: lower Panel A, red arrow), derived from the revealed ‘tethered ligand’. The 
data suggest that the peptide docks with extracellular loop-2. However, there is NO difference (lower 
panel B: NO shift in trypsin sensitivity) in the ability of the trypsin-unmasked tethered ligand sequence, 
SLIGRL--- to activate the mutated ‘PRR’ extracellular loop-2 receptor (SR/RR), compared with the 
wild-type ‘PEE’ EL2 receptor (SR/EE). Thus, the receptor-docking sites for signalling by the synthetic 
PAR-activating peptide and the proteinase-unmasked tethered ligands differ. Adapted from Al-Ani et al., 
2002 with permission. 
Figure 4. A minimal PAR2 tethered ligand sequence (SL----) is required for calcium signalling. The 
proteinase-revealed ‘tethered ligand’ (TL) sequence of PAR2 was mutated so that trypsin unmasked 
different mutated ‘TL’ sequences with alanine substitutions (sequences shown in boxes) in the first six 
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amino acids.  When revealed, the mutated TL-sequences, SLAAAA--- and SAIGRL--- were able to 
stimulate calcium signalling (red arrows, upper curves), whereas the sequences, AAIGRL--- and 
LSIGRL--- did not (blue arrows, bottom). Adapted from Al-Ani et al., 2004, with permission. 
Figure 5. Biased PAR2 signalling by the PAR-activating peptide, SLAAAA-NH2. The PAR2-activating 
peptide with multiple alanine substitutions does not trigger calcium signalling like the full PAR2 peptide 
agonist (2-furoyl-LIGRLO-NH2: upper). However,  SLAAAA-NH2 does nonetheless activate 
MAPKinase signalling as a ‘biased’ PAR2 agonist (lower). Adapted from Ramachandran et al., 2009, 
with permission. 
 
Figure 6. The mobile or floating receptor model of receptor action. The scheme shows how an individual 
GPCR capable of coupling to multiple G-proteins, as well as generating a beta-arrestin internalized 
signalling scaffold, can in principle be selectively activated by a ‘biased’ agonist to signal via only one 
of the available G-proteins (dotted lines). 
 
Figure 7. Monitoring PAR2 internalization and arrestin interaction upon activation. 7A. PAR2 
internalization (red arrows) after activation by either trypsin (TRP) or PAR2-activating peptide (SLI). 
7B. Monitoring PAR2-beta-arrestin interaction by BRET after activation by trypsin (left) or PAR-
activating peptide (right). Internalization is quantified (left histograms) by morphometric analysis of 
internalized receptor clusters (Green dots, red arrow, Panel A). PAR2-beta-arrestin interactions 
stimulated by either trypsin (7B, Panel A) or PAR2-activating peptide (7B, Panel B) are quantified by 
measuring the YFP fluorescence emission at 540 nm relative to the rLUC signal (YFP/rLUC), caused by 
bioluminescence resonance-energy-transfer (Panel B), as shown by the cartoon a the bottom of 7B. 
 
Figure 8. Biased signalling by a mutated rat PAR2 tethered ligand without receptor internalization. 8A. 
Activation of PAR2 MAPKinase signalling by the trypsin-exposed mutated tethered ligand, 
//L
37
S
38
IGRL--- (rPAR2-L
37
S
38
). 8B. Lack of internalization of mutant PAR2 (rPAR2-L
37
S
38
) activated 
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by the trypsin-exposed tethered ligand, //LSIGRL--- . PAR2 was mutated so that trypsin cleavage 
(shown by //) at the R
36
//L
37
SIGRL--- sequence unmasks the tethered ligand sequence, L
37
S
38
IGRL--- 
(rPAR2-L
37
S
38
), which activates MAPKinase to the same level as for trypsin-activated wild-type 
receptor [8A, histograms (left) and western blot (right)]. However, the trypsin-unmasked mutant 
tethered ligand (rPAR2-L
37
S
38
) does not activate calcium signalling (Figure 4, blue arrow at the bottom, 
X-axis) and does not trigger receptor internalization (lower-right image, Figure 8B; red arrow, right 
histograms). In contrast, peptide-driven receptor activation causes internalization of both the wild-type 
and mutant rPAR2-L
37
S
38
 receptors (blue two-way arrow, right-hand histograms, Figure 8B). 
   
Figure 9. Biased PAR1 signalling (MAPKinase, but not calcium) by purified cockroach allergen serine 
proteinase E1. A. Biotin-labeling of isolated cockroach proteinases E1, E2 and E3 with the biotin-serine 
proteinase activity-based probe. B. Activation of MAPKinase in PAR1-expressing cells (Western blot 
signal: P-MAPK) by cockroach proteinase E1 (0.5 and 4 U/ml enzyme activity) compared with 
thrombin (1U/ml). C. Calcium signalling stimulated by thrombin (0.5 U/ml: red arrow, left panel E530) 
but not by E1 proteinase (4 U/ml: blue arrow, right panel, E530) at concentrations that nonetheless 
trigger MAPKinase activation (Fig. 9B and data not shown).  
 
Figure 10. Neutrophil elastase stimulates ‘biased’ PAR2 signalling (MAPKinase; but not calcium) 
without triggering a PAR2-beta-arrestin interaction. 10A. Neutrophil elastase, which does not cause a 
calcium signal on its own, disarms PAR2 preventing trypsin-stimulated (blue arrow) but not peptide-
stimulated PAR2 calcium signalling (increase in E530).  10B. Elastase activation of PAR2 does not 
trigger a beta-arrestin interaction (bottom curve), whereas trypsin and a PAR-activating peptide (2-
furoyl-LIGRLO-NH2) do (red arrow: upper curves). 
 
Figure 11. Neutrophil elastase (NE) does not stimulate PAR2 internalization whereas trypsin does. 
Trypsin-stimulated PAR2 internalization (upper-right panel, red arrows) was quantified by 
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morphometric analysis of internalized receptor clusters (green dots: arrows, quantified in the right filled 
histogram: red arrow). No internalization was observed when cells were treated with neutrophil elastase 
(NE, lower left quadrant image; right-hand histogram, NE, black arrow). 
 
Figure 12. The PAR2 antagonist GB88 blocks calcium signalling but activates PAR2 MAPKinase 
signalling. A. Pretreatment of cells with GB88 Blocked PAR-agonist (2-furoyl-LIGRLO-NH2)-
stimulated calcium signalling (histograms, Panel A), but B. activated MAPKinase signalling (phospho-
p42/44; P-MAPK) relative to ‘no-treatment’ (NT) cells (% p42/44 relative to NT cells). The level of the 
GB88-stimulated  MAPKinase  was equivalent to that triggered by either trypsin (TRP) or a PAR2-
activating peptide (SL: SLIGRL-NH2). 
 
Figure 13. The PAR2 antagonist, GB88, that stimulates MAPKinase, promotes beta-arrestin interactions 
(A), but does not either cause receptor internalization on its own (B. left panel) or block agonist-
triggered PAR2 internalization (B. middle and right panels). The concentration dependence of GB88-
stimulated PAR2 interaction with beta-arrestin is shown in Panel A (Upper). PAR2 internalization 
caused by either trypsin (middle panel, Figure 13B) or a PAR2 peptide agoinist (2furoyl-LIGRLO-NH2: 
2fL: right panel, Figure 13B) is shown by the white arrows. The scale marker (white bar) represents 5 
microns (µm).  
 
Figure 14. Pepducin P2pal-18S blocks calcium signalling but does not affect agonist-stimulated PAR2-
beta-arrestin interactions. A. Calcium signalling (E580) stimulated by 2-furoyl-LIGRLO-NH2 (2fLI) in 
PAR2-expressing HEK cells (upward deflection of tracing) is blocked by pretreatment of the cells with 
P2pal-18S-pepducin (arrow on right). B. However, treatment of cells with the same concentrations of  
pepducin P2pal-18S that block calcium signalling (A, upper) does not affect the trypsin-stimulated 
interaction of PAR2 with beta-arrestin monitored by BRET (red arrow: histograms on right).  
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Figure 15. PAR2 antagonists, GB88 and P2pal-18S-pepducin, block paw inflammation. A. Rat paw 
oedema caused by the intraplantar administration of a PAR2-activating peptide (2-furoyl-LIGRLO-NH2) 
was blocked (downward red arrow) by the systemic administration of GB88 . B. Similarly, mouse paw 
inflammation (tissue neutrophil infiltration: cell count/field) caused by the intraplantar administration of 
λ-carrageenan/kaolin (solid histogram, right panel) was attenuated by the subcutaneous administration of 
P2pal-18S-pepducin (middle grey histogram, right panel) to the level observed in PAR2-null mice (open 
histogram, right panel). Data adapted from Suen et al., 2012 with permission (Left panel) and by 
independent morphometric analysis of photomicrographs shown in Figure 4 of Sevigny et al., 2011. 
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Table 1: The proteinase-activated receptor (PAR) family, their canonical and non-
canonical proteolytically-unmasked tethered ligands and their non-biased and 
biased peptide agonists
1 
 
Canonical and Non-Canonical PAR Cleavage Sites and Tethered Ligand Sequences 
RECEPTOR/GENE 
DESIGNATION 
CANONICAL 
TETHERED 
LIGAND 
(HUMAN) 
RECEPTOR-
SELECTIVE PAR-
ACTIVATING 
PEPTIDES 
NON-CANONICAL 
TETHERED 
LIGANDS 
BIASED PAR-
ACTIVATING 
PEPTIDES 
PAR1/F2R --//SFLLRN--  TFLLR-NH2 MMP1: --//PRSFLLRN-- 
APC: --//NPNDKYEPF-- 
PRSFLLRN;  
NPNDKYEPF; 
YFLLRN 
PAR2/F2RL1 --//SLIGKV-- SLIGRL-NH2; 
2-furoyl-LIGRL-NH2 
NE: --//VLTGKL-- SLAAAA- NH2 
PAR3/F2RL2 --//TFRGAP-- TL-derived peptides 
activate PARs 1 & 2 
NOT KNOWN NOT KNOWN 
PAR4/F2RL3 --//GYPGQV-- AYPGQV-NH2; 
AYPGKV-NH2 
NOT KNOWN NOT KNOWN 
 
1. Footnote. The ‘canonical’ PAR ‘tethered ligands’ resulting from cleavage-activation of 
the PARs (cleavage site shown as: //) correspond to the sequences of the receptor-
selective PAR-activating peptides. The sequences of synthetic receptor-selective 
‘canonical’ PAR-activating peptides based on the thrombin (PARs 1 and 4) or trypsin 
(PAR2)-unmasked tethered ligands are shown along with ‘non-canonical’ tethered 
ligands unmasked (//) by neutrophil elastase (NE: PAR 2), matrix-metalloproteinase-1 
(MMP1: PAR1) or activated protein-C (APC: PAR1). Further, biased synthetic PAR-
activating peptides derived from the ‘noncanonical’ enzyme-unmasked tethered ligands 
are shown in the last column on the right. 
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Figure 1. Proteinase-mediated Signalling  
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Figure 2. Activation of PAR2 by proteinase or PAR-activating peptide  
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Figure 3. Differences in signalling by PAR2-AP vs tethered ligand in a PAR2 mutant receptor  
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Figure 4. Minimal PAR2 tethered ligand sequence required for calcium signalling  
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Figure 5. Biased PAR2 signalling by the PAR-activating peptide SLAAAA-amide  
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Figure 6. The mobile or floating receptor model of receptor action  
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Figure 7A. PAR2 internalization after activation by either trypsin (TRP) or PAR2-activating peptide (SLI)  
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Figure 7B. PAR2 internalization after activation by either trypsin (TRP) or PAR2-activating peptide (SLI)  
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Figure 8A. Activation of PAR2 MAPKinase signalling by a mutated trypsin-exposed tethered ligand, /LSIGRL--
-  
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Figure 8B. Activation of PAR2 MAPKinase signalling by a mutated trypsin-exposed tethered ligand, /LSIGRL--
-  
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Figure 9. Biased PAR1 signalling (MAPKinase, not calcium) by cockroach allergen serine proteinase E1  
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Figure 10A. Biased PAR2 activation by neutrophil elastase: Triggering of MAPKinase but not calcium 
signalling  
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Figure 10B. Elastase activation of PAR2 does not trigger a beta-arrestin interaction, whereas trypsin and a 
PAR-activating peptide (2-furoyl-LIGRLO-amide) do.  
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Figure 11. Neutrophil elastase (NE) does not stimulate PAR2 internalization whereas trypsin does  
254x190mm (96 x 96 DPI)  
 
 
Page 45 of 49
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
  
 
 
Figure 12. The PAR2 antagonist GB88 blocks calcium signalling but activates PAR2 MAPKinase  
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Figure 13. The PAR2 antagonist GB88 promotes PAR2-arrestin interaction, does not stimulate receptor 
internalization and does not block trypsin or PAR2-AP-triggered PAR2 internalization  
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Figure 14. Pepducin P2pal-18S blocks calcium signalling but does not affect agonist-stimulated PAR2-beta-
arrestin interactions  
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Figure 15. PAR2 antagonists GB88 and P2;al-18S block paw inflammation  
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